Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1440-1444

  Daver, Naval ^a   Shastri, Aditi ^a   Kadia, Tapan ^a   Quintas Cardama, Alfonso ^a   Jabbour, Elias ^a   Konopleva, Marina ^a   O'Brien, Susan ^a   Pierce, Sherry ^a   Zhou, Lingsha ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anemia; Myelofibrosis; Pomalidomide

Indexed keywords

HEMOGLOBIN; POMALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BASOPHILIA; BLOOD TOXICITY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; MYELOFIBROSIS; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SENSORY NEUROPATHY; SYNDROME DELINEATION; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; WEAKNESS;

ANEMIA; MYELOFIBROSIS; POMALIDOMIDE;

AGED; ANEMIA; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84886771903     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.007     Document Type: Article

References (40)

1. Lambert J.R., Everington T., Linch D.C., Gale R.E. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 2009, 114:3018-3023.
2. Beer P.A., Jones A.V., Bench A.J., Goday-Fernandez A., Boyd E.M., Vaghela K.J., et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 2009, 144:904-908.
3. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005, 23:8520-8530.
4. Schmitt A., Jouault H., Guichard J., Wendling F., Drouin A., Cramer E.M. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000, 96:1342-1347.
5. Xu M., Bruno E., Chao J., Huang S., Finazzi G., Fruchtman S.M., et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood 2005, 105:4508-4515.
6. Mesa R.A., Niblack J., Wadleigh M., Verstovsek S., Camoriano J., Barnes S., et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007, 109:68-76.
7. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J.T., Morra E., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
8. Huang J., Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009, 83:154-155.
9. Cervantes F., Alvarez-Larran A., Domingo A., Arellano-Rodrigo E., Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005, 129:771-775.
10. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
11. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363:1117-1127.
12. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008, 22:23-30.
13. Schey S.A., Fields P., Bartlett J.B., Clarke I.A., Ashan G., Knight R.D., et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004, 22:3269-3276.
14. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
15. Thomas D.A., Giles F.J., Albitar M., Cortes J.E., Verstovsek S., Faderl S., et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006, 106:1974-1984.
16. Abgrall J.F., Guibaud I., Bastie J.N., Flesch M., Rossi J.F., Lacotte-Thierry L., et al. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 2006, 91:1027-1032.
17. Marchetti M., Barosi G., Balestri F., Viarengo G., Gentili S., Barulli S., et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004, 22:424-431.
18. Mesa R.A., Steensma D.P., Pardanani A., Li C.Y., Elliott M., Kaufmann S.H., et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003, 101:2534-2541.
19. Barosi G., Grossi A., Comotti B., Musto P., Gamba G., Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001, 114:78-83.
20. Quintas-Cardama A., Kantarjian H.M., Manshouri T., Thomas D., Cortes J., Ravandi F., et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009, 27:4760-4766.
21. Tefferi A., Cortes J., Verstovsek S., Mesa R.A., Thomas D., Lasho T.L., et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108:1158-1164.
22. Bartlett J.B., Dredge K., Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004, 4:314-322.
23. Galustian C., Meyer B., Labarthe M.C., Dredge K., Klaschka D., Henry J., et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009, 58:1033-1045.
24. Tefferi A., Verstovsek S., Barosi G., Passamonti F., Roboz G.J., Gisslinger H., et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009, 27:4563-4569.
25. Tefferi A., Barosi G., Mesa R.A., Cervantes F., Deeg H.J., Reilly J.T., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108:1497-1503.
26. Mesa R.A., Pardanani A.D., Hussein K., Wu W., Schwager S., Litzow M.R., et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010, 85:129-130.
27. Vardiman J.W., Brunning R., Harris N.L. WHO histological classification of chronic myeloproliferative diseases. World Health Organization classification of tumors: tumors of the haematopoietic and lymphoid tissues 2001, 17-44. International Agency for Research on Cancer Press, Lyon, France. E.S. Jaffe, N. Harris, H. Stein (Eds.).
28. Gale R.P., Barosi G., Barbui T., Cervantes F., Dohner K., Dupriez B., et al. What are RBC-transfusion-dependence and -independence. Leuk Res 2011, 35:8-11.
29. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011, 29:392-397.
30. Passamonti F., Cervantes F., Vannucchi A.M., Morra E., Rumi E., Pereira A., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115:1703-1708.
31. Begna K.H., Mesa R.A., Pardanani A., Hogan W.J., Litzow M.R., McClure R.F., et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011, 25:301-304.
32. Begna K.H., Pardanani A., Mesa R., Litzow M.R., Hogan W.J., Hanson C.A., et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012, 87:66-68.
33. Moutouh-de Parseval L.A., Verhelle D., Glezer E., Jensen-Pergakes K., Ferguson G.D., Corral L.G., et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest 2008, 118:248-258.
34. Verhelle D., Corral L.G., Wong K., Mueller J.H., Moutouh-de Parseval L., Jensen-Pergakes K., et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007, 67:746-755.
35. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163:380-386.
36. Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 2004, 28:325-332.
37. Dredge K., Marriott J.B., Macdonald C.D., Man H.W., Chen R., Muller G.W., et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002, 87:1166-1172.
38. Pardanani A., Begna K., Finke C., Lasho T., Tefferi A. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol 2011, 86:343-345.
39. Shastri A., Cortes J.E., Jabbour E.J., Zhou L., Schroeder K., Kantarjian H.M., et al. A phase II study of low-dose pomalidomide (0.5mg/day) and prednisone combination therapy in patients with myelofibrosis and significant anemia. Blood ASH annual meeting abstract 2012, 120.
40. Schlenk R.F., Reiter A., Gattermann N., Hebart H., Jost E., Platzbecker U., et al. Pomalidomide in myelofibrosis with cytopenia: first results of the Mpnsg 01-09 study (ClinicalTrials.gov Identifier: NCT00949364). Blood ASH annual meeting abstract 2012, 120.